Showing results (121-130 of 127) with videos related to
Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 127 results.
Hematological Oncology|May 24, 2022
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trialsAntonella Bruzzese, Daniele Derudas, Monica Galli, et al.Medrxiv : the Preprint Server for Health Sciences|August 15, 2020
Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population LevelsThomas M Snyder, Rachel M Gittelman, Mark Klinger, et al.Haematologica|March 6, 2025
Comparison of isatuximab-pomalidomide-dexamethasone <i>versus</i> elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world dataEnrica Antonia Martino, Annalisa Pitino, Massimo Offidani, et al.Frontiers in Immunology|January 22, 2025
Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levelsThomas M Snyder, Rachel M Gittelman, Mark Klinger, et al.European Journal of Haematology|March 19, 2025
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 PatientsFortunato Morabito, Enrica Antonia Martino, Monica Galli, et al.Open Forum Infectious Diseases|March 19, 2026
Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA RegistryJon Salmanton-García, Francesco Marchesi, Erica Mackenzie, et al.American Journal of Hematology|December 23, 2024
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA ReportJon Salmanton-García, Francesco Marchesi, Milan Navrátil, et al.Pageof 13